Skip to main content
Top
Published in: Archives of Virology 12/2010

Open Access 01-12-2010 | Original Article

Hepatitis C virus quasispecies in chronically infected children subjected to interferonribavirin therapy

Authors: Magdalena Figlerowicz, Paulina Jackowiak, Piotr Formanowicz, Paweł Kędziora, Magdalena Alejska, Nelli Malinowska, Jacek Błażewicz, Marek Figlerowicz

Published in: Archives of Virology | Issue 12/2010

Login to get access

Abstract

Accumulating evidence suggests that certain features of hepatitis C virus (HCV), especially its high genetic variability, might be responsible for the low efficiency of anti-HCV treatment. Here, we present a bioinformatic analysis of HCV-1a populations isolated from 23 children with chronic hepatitis C (CHC) subjected to interferon–ribavirin therapy. The structures of the viral quasispecies were established based on a 132-amino-acid sequence derived from E1/E2 protein, including hypervariable region 1 (HVR1). Two types of HCV populations were identified. The first type, found in non-responders, contained a small number of closely related variants. The second type, characteristic for sustained responders, was composed of a large number of distantly associated equal-rank variants. Comparison of 445 HVR1 sequences showed that a significant number of variants present in non-responding patients are closely related, suggesting that certain, still unidentified properties of the pathogen may be key factors determining the result of CHC treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alberti A, Benvegnu L (2003) Management of hepatitis C. J Hepatol 38(Suppl 1):104–118CrossRef Alberti A, Benvegnu L (2003) Management of hepatitis C. J Hepatol 38(Suppl 1):104–118CrossRef
2.
go back to reference Canobio S, Guilbert CM, Troesch M, Samson J, Lemay M, Pelletier VA, Bernard-Bonnin AC, Kozielski R, Lapointe N, Martin SR, Soudeyns H (2004) Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 42:4365–4369CrossRefPubMed Canobio S, Guilbert CM, Troesch M, Samson J, Lemay M, Pelletier VA, Bernard-Bonnin AC, Kozielski R, Lapointe N, Martin SR, Soudeyns H (2004) Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 42:4365–4369CrossRefPubMed
3.
go back to reference Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ (1996) Basic concepts in RNA virus evolution. Faseb J 10:859–864PubMed Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ (1996) Basic concepts in RNA virus evolution. Faseb J 10:859–864PubMed
4.
go back to reference Domingo E, Escarmis C, Lazaro E, Manrubia SC (2005) Quasispecies dynamics and RNA virus extinction. Virus Res 107:129–139CrossRefPubMed Domingo E, Escarmis C, Lazaro E, Manrubia SC (2005) Quasispecies dynamics and RNA virus extinction. Virus Res 107:129–139CrossRefPubMed
5.
go back to reference Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99:3081–3086CrossRefPubMed Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99:3081–3086CrossRefPubMed
6.
go back to reference Farci P, Quinti I, Farci S, Alter HJ, Strazzera R, Palomba E, Coiana A, Cao D, Casadei AM, Ledda R, Iorio R, Vegnente A, Diaz G, Tovo PA (2006) Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA 103:8475–8480CrossRefPubMed Farci P, Quinti I, Farci S, Alter HJ, Strazzera R, Palomba E, Coiana A, Cao D, Casadei AM, Ledda R, Iorio R, Vegnente A, Diaz G, Tovo PA (2006) Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA 103:8475–8480CrossRefPubMed
7.
go back to reference Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2):25–31CrossRefPubMed Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2):25–31CrossRefPubMed
8.
go back to reference Figlerowicz M, Alejska M, Kurzyńska-Kokorniak A, Figlerowicz M (2003) Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med Res Rev 23:488–518CrossRefPubMed Figlerowicz M, Alejska M, Kurzyńska-Kokorniak A, Figlerowicz M (2003) Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med Res Rev 23:488–518CrossRefPubMed
9.
go back to reference Figlerowicz M, Służewski W, Kowala-Piaskowska A, Mozer-Lisewska I (2004) Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr 163:265–267CrossRefPubMed Figlerowicz M, Służewski W, Kowala-Piaskowska A, Mozer-Lisewska I (2004) Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr 163:265–267CrossRefPubMed
10.
go back to reference Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P (2003) Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J Med Virol 69:350–356CrossRefPubMed Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P (2003) Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J Med Virol 69:350–356CrossRefPubMed
11.
go back to reference Gerlach TJ, Zachoval R, Gruener N, Jung M-C, Ulsenheimer A, Schraut W, Schirren A, Waechtler M, Backmund M, Diepolder HGP (2001) Acute hepatitis C: natural course and response to antiviral treatment. Hepatology 34:A341 Gerlach TJ, Zachoval R, Gruener N, Jung M-C, Ulsenheimer A, Schraut W, Schirren A, Waechtler M, Backmund M, Diepolder HGP (2001) Acute hepatitis C: natural course and response to antiviral treatment. Hepatology 34:A341
12.
go back to reference Gerotto M, Resti M, Dal Pero F, Migliorato I, Alberti A, Bortolotti F (2006) Evolution of hepatitis C virus quasispecies in children with chronic hepatitis C. Infection 34:62–65CrossRefPubMed Gerotto M, Resti M, Dal Pero F, Migliorato I, Alberti A, Bortolotti F (2006) Evolution of hepatitis C virus quasispecies in children with chronic hepatitis C. Infection 34:62–65CrossRefPubMed
13.
go back to reference Gismondi MI, Becker PD, Diaz Carrasco JM, Guzman CA, Campos RH, Preciado MV (2009) Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. J Viral Hepat 16:332–339CrossRefPubMed Gismondi MI, Becker PD, Diaz Carrasco JM, Guzman CA, Campos RH, Preciado MV (2009) Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. J Viral Hepat 16:332–339CrossRefPubMed
14.
go back to reference Hadziyannis S, Cheinquer JH, Morgan T, Diago M, Jensen DM, Sette H Jr, Ramadori G (2002) Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 36(Supp 1):3CrossRef Hadziyannis S, Cheinquer JH, Morgan T, Diago M, Jensen DM, Sette H Jr, Ramadori G (2002) Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 36(Supp 1):3CrossRef
16.
go back to reference Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21:379–384CrossRefPubMed Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21:379–384CrossRefPubMed
17.
go back to reference Kumar S, Nei M, Dudley J, Tamura K (2008) MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 9:299–306CrossRefPubMed Kumar S, Nei M, Dudley J, Tamura K (2008) MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 9:299–306CrossRefPubMed
18.
go back to reference McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485–1492CrossRefPubMed McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485–1492CrossRefPubMed
19.
go back to reference Mizokami M, Ohno T (1998) Determination of HCV quasispecies by cloning and sequencing. In: Lau JYN (ed) Hepatitis C protocols. Humana Press, New Jersey, USA, pp 207–211CrossRef Mizokami M, Ohno T (1998) Determination of HCV quasispecies by cloning and sequencing. In: Lau JYN (ed) Hepatitis C protocols. Humana Press, New Jersey, USA, pp 207–211CrossRef
20.
go back to reference Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ (2008) Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J 5:78CrossRefPubMed Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ (2008) Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J 5:78CrossRefPubMed
21.
go back to reference Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D (1998) Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 54:256–264CrossRefPubMed Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D (1998) Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 54:256–264CrossRefPubMed
22.
go back to reference Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75:5703–5710CrossRefPubMed Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75:5703–5710CrossRefPubMed
23.
go back to reference Pond SL, Frost SD (2005) Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21:2531–2533CrossRefPubMed Pond SL, Frost SD (2005) Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21:2531–2533CrossRefPubMed
24.
go back to reference Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. international hepatitis interventional therapy group (IHIT). Lancet 352:1426–1432CrossRefPubMed Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. international hepatitis interventional therapy group (IHIT). Lancet 352:1426–1432CrossRefPubMed
25.
go back to reference Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, Sanchez-Tapias JM, Saiz JC (2005) Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 86:1067–1075CrossRefPubMed Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, Sanchez-Tapias JM, Saiz JC (2005) Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 86:1067–1075CrossRefPubMed
26.
go back to reference Quesnel-Vallieres M, Lemay M, Lapointe N, Martin SR, Soudeyns H (2008) HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. J Clin Virol 43:236–240CrossRefPubMed Quesnel-Vallieres M, Lemay M, Lapointe N, Martin SR, Soudeyns H (2008) HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. J Clin Virol 43:236–240CrossRefPubMed
27.
go back to reference Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol 85:3173–3188CrossRefPubMed Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol 85:3173–3188CrossRefPubMed
28.
go back to reference Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596–1599CrossRefPubMed Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596–1599CrossRefPubMed
29.
go back to reference Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 26:6–13CrossRefPubMed Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 26:6–13CrossRefPubMed
30.
go back to reference Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, Watanabe M (2004) Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 29:89–96CrossRefPubMed Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, Watanabe M (2004) Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 29:89–96CrossRefPubMed
Metadata
Title
Hepatitis C virus quasispecies in chronically infected children subjected to interferon–ribavirin therapy
Authors
Magdalena Figlerowicz
Paulina Jackowiak
Piotr Formanowicz
Paweł Kędziora
Magdalena Alejska
Nelli Malinowska
Jacek Błażewicz
Marek Figlerowicz
Publication date
01-12-2010
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 12/2010
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-010-0789-7

Other articles of this Issue 12/2010

Archives of Virology 12/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.